Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | FDPS | P14324 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9000615 | 0.95 | POLB (0.42) | POLBFDPSSMPD1 | |
| SCHEMBL9234014 | 0.93 | SMPD1 (0.42) | POLBFDPSSMPD1 | |
| SCHEMBL3674519 | 0.93 | SMPD1 (0.42) | POLBFDPSSMPD1 | |
| SCHEMBL10847001 | 0.91 | POLB (0.41) | POLBCA1CA2CYP3A4TSHR | |
| SCHEMBL1051880 | 0.89 | POLB (0.53) | POLBFDPSCYP3A4TSHRALDH1A1 | |
| SCHEMBL10451891 | 0.88 | CA1 (0.49) | POLBFDPSCA1CA2CYP3A4 | |
| SCHEMBL8616279 | 0.88 | POLB (0.39) | POLBCA1CA2CYP3A4TSHR | |
| SCHEMBL1759172 | 0.86 | POLB (0.38) | POLBCA1CA2CYP3A4TSHR | |
| SCHEMBL720148 | 0.86 | POLB (0.38) | POLBCA1CA2CYP3A4L3MBTL1 | |
| SCHEMBL1903133 | 0.84 | CA2 (0.42) | POLBFDPSCA1CA2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109666637-B | Application of Vgamma 9 Vdelta 2T and agonist thereof in treatment of hepatic fibrosis, liver cirrhosis and liver cancer | 清华大学 | 2023-04-11 | — | — | CN | disclosed |
| EP-2203161-B1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | UNIV INDIANA RES & TECH CORP (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20170210711-A1 | COMPETITIVE PPAR-GAMMA ANTAGONISTS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210711-A1 | COMPETITIVE PPAR-GAMMA ANTAGONISTS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2017-07-27 | — | — | US | disclosed |
| US-9089605-B2 | Quinone derivatives, pharmaceutical compositions, and uses thereof | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-9089605-B2 | Quinone derivatives, pharmaceutical compositions, and uses thereof | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-20100297113-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2010-11-25 | — | — | US | disclosed |
| EP-2203161-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Indiana University Research and Technology Corporation (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009042544-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
| US-5698541-A | DISEASES OF CALCIUM METABOLISM; OSTEOPOROSIS | BOEHRINGER MANNHEIM GMBH (DE) | 1997-12-16 | — | — | US | disclosed |
| EP-0655439-A2 | 5,6-Bicyclic glycoprotein IIb IIIa antagonists useful in inhibition of platelet aggregation | ELI LILLY AND COMPANY (US) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210711-A1 | COMPETITIVE PPAR-GAMMA ANTAGONISTS | PPARA, PPARD, PPARG | POLB 169/4885FDPS 2274/4885CA1 4880/4885 |
| US-20100297113-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | APEX1, NQO1, REV1 | POLB 264/4885FDPS 1009/4885CA1 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.